Nanocarrier systems loaded with IR780, iron oxide nanoparticles and chlorambucil for cancer theragnostics

• Phuong-Thao Dang-Luong,
• Hong-Phuc Nguyen,
• Loc Le-Tuan,
• Xuan-Thang Cao,
• Vy Tran-Anh and
• Hieu Vu Quang

Beilstein J. Nanotechnol. 2024, 15, 180–189, doi:10.3762/bjnano.15.17

• endothelial growth factor (VEGF) receptors [38][39]. The folate receptor was selected as a targeting modality in our investigation. The findings of the uptake assays (Figure 3), fluorescent assay (Supporting Information File 1, Figure S2) and the cytotoxicity testing (Figure 4) revealed that F127-folate@NP

• our NPs. Second, the ligand attached to the nanoparticles would aid in the accumulation of nanoparticles within the cells. Numerous studies have employed different ligands to target overexpressed receptors on cancer cells, including folate receptors [13][37], integrins [36][37], and vascular

Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics

• Mamta Kumari,
• Amitabha Acharya and
• Praveen Thaggikuppe Krishnamurthy

Beilstein J. Nanotechnol. 2023, 14, 912–926, doi:10.3762/bjnano.14.75

• , JAK2/STAT3 pathway) [25][26][27][28], and proangiogenic factors (e.g., vascular endothelial growth factor receptor, epidermal growth factor receptor (EGFR), platelet derived growth factor, and basic fibroblast growth factor) [29][30]. Further, overexpression of cancer receptors, such as estrogen

Overview of mechanism and consequences of endothelial leakiness caused by metal and polymeric nanoparticles

• Magdalena Lasak and
• Karol Ciepluch

Beilstein J. Nanotechnol. 2023, 14, 329–338, doi:10.3762/bjnano.14.28

• vasoconstrictions factors (e.g., thromboxane, prostaglandin, and endothelin-1), regulating vessel tension and, thus, blood flow and pressure [4][5][6][7][8]. The endothelium also produces mediators involved in angiogenic processes (e.g., vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF

Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer

• Filip Gorachinov,
• Fatima Mraiche,
• Diala Alhaj Moustafa,
• Ola Hishari,
• Yomna Ismail,
• Jensa Joseph,
• Maja Simonoska Crcarevska,
• Marija Glavas Dodov,
• Nikola Geskovski and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2023, 14, 240–261, doi:10.3762/bjnano.14.23

• the Ras-Raf-Erk pathway, promoting angiogenesis via hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF) signaling [29][30][31]. According to preclinical data, a combination therapy consisting of erlotinib and cisplatin targets angiogenesis and manifests synergistic and

• include ανβ3 integrin, aminopeptidase N (CD13), lymphocyte homing receptor (CD44), programmed death ligand-1 (CD274), folate receptor protein, nucleolin receptor, epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), human epidermal growth factor receptor 2 (HER2

Micro- and nanotechnology in biomedical engineering for cartilage tissue regeneration in osteoarthritis

• Zahra Nabizadeh,
• Mahmoud Nasrollahzadeh,
• Hamed Daemi,
• Mohamadreza Baghaban Eslaminejad,
• Ali Akbar Shabani,
• Mehdi Dadashpour,
• Majid Mirmohammadkhani and
• Davood Nasrabadi

Beilstein J. Nanotechnol. 2022, 13, 363–389, doi:10.3762/bjnano.13.31

Use of nanosystems to improve the anticancer effects of curcumin

• Andrea M. Araya-Sibaja,
• Norma J. Salazar-López,
• Krissia Wilhelm Romero,
• José R. Vega-Baudrit,
• J. Abraham Domínguez-Avila,
• Carlos A. Velázquez Contreras,
• Ramón E. Robles-Zepeda,
• Mirtha Navarro-Hoyos and
• Gustavo A. González-Aguilar

Beilstein J. Nanotechnol. 2021, 12, 1047–1062, doi:10.3762/bjnano.12.78

• ][30][31][32][33][34][35][36][37][38]. Carcinoembryonic antigen (CEA); vascular endothelial growth factor (VEGF); cancer antigen 15.3 (CA15.3); DNA adduct 3-(2-deoxy-β-di-erythro-pentafuranosyl)pyrimido[1,2-α]purin-10(3H)-one (M1G); enzyme cyclooxygenase-2 (COX-2); colorectal aberrant crypt foci (ACF

Silver nanoparticles induce the cardiomyogenic differentiation of bone marrow derived mesenchymal stem cells via telomere length extension

• Khosro Adibkia,
• Ali Ehsani,
• Asma Jodaei,
• Ezzatollah Fathi,
• Raheleh Farahzadi and
• Mohammad Barzegar-Jalali

Beilstein J. Nanotechnol. 2021, 12, 786–797, doi:10.3762/bjnano.12.62

• cell marker), smooth muscle actin (SMA) (as smooth muscle cell marker), vascular endothelial growth factor (VEGF) (as vasculogenesis marker), and von Willebrand factor (VWF) (as endothelial cell marker) were investigated in this panel. As shown in Figure 7, no significant increase was seen in the

Poly(1-vinylimidazole) polyplexes as novel therapeutic gene carriers for lung cancer therapy

• Gayathri Kandasamy,
• Elena N. Danilovtseva,
• Vadim V. Annenkov and
• Uma Maheswari Krishnan

Beilstein J. Nanotechnol. 2020, 11, 354–369, doi:10.3762/bjnano.11.26

• Russian Academy of Sciences, 3, Ulan-Batorskaya St., P.O. Box 278, Irkutsk, 664033, Russia 10.3762/bjnano.11.26 Abstract The present work explores the ability of poly(1-vinylimidazole) (PVI) to complex small interfering RNA (siRNA) silencing vascular endothelial growth factor (VEGF) and the in vitro

• ); vascular endothelial growth factor (VEGF); Introduction Gene therapy is a promising strategy that can be employed in the treatment of many hereditary disorders as well as diseases triggered by sporadic mutations including many forms of cancer. However, the therapeutic potential of gene therapy is yet to

• endosome is observed as yellow fluorescence (red arrows). The green emission was recorded at 488 nm while the red emission was captured at 568 nm. The blue fluorescence of Hoechst 33258 was recorded at 405 nm. Expression of vascular endothelial growth factor (VEGF) mRNA in A549 cells analyzed by RT-PCR

Tight junction between endothelial cells: the interaction between nanoparticles and blood vessels

• Yue Zhang and
• Wan-Xi Yang

Beilstein J. Nanotechnol. 2016, 7, 675–684, doi:10.3762/bjnano.7.60

• inhibited (79%) by silver nanoparticles (2–6 nm) [80]. Also, AuNPs have the ability to prevent vascular endothelial growth factor (VEGF)- and interleukin-1 beta (IL-1β)-induced proliferation and migration in bovine retinal pigment epithelial cells (BRPEs) through the suppression of the Src kinase pathway

Biocompatibility of cerium dioxide and silicon dioxide nanoparticles with endothelial cells

• Claudia Strobel,
• Martin Förster and
• Ingrid Hilger

Beilstein J. Nanotechnol. 2014, 5, 1795–1807, doi:10.3762/bjnano.5.190

• granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-1 α (IL-1α), tumor necrosis factor α (TNF-α), interferon gamma-induced protein 10 (IP-10), plasminogen activator inhibitor-1 (PAI-1), platelet-derived growth factor (PDGF-BB), epidermal growth factor (EGF) and vascular endothelial growth

• factor (VEGF) of HUVEC exposed to CeO2 nanoparticles for 24 h (Figure 5). In general, the release of these proteins was lowest after treatment with the small-sized CeO2 nanoparticles (sample #A) compared to their large-sized counterparts (sample #B). This could be caused, at least in part, by protein

Mimicking exposures to acute and lifetime concentrations of inhaled silver nanoparticles by two different in vitro approaches

• Fabian Herzog,
• Kateryna Loza,
• Sandor Balog,
• Martin J. D. Clift,
• Matthias Epple,
• Peter Gehr,
• Alke Petri-Fink and
• Barbara Rothen-Rutishauser

Beilstein J. Nanotechnol. 2014, 5, 1357–1370, doi:10.3762/bjnano.5.149

• proliferation and migration (chemotaxis) both decreased, and the release of cytokines was affected. Increased IL-8 and decreased IL-6 and vascular endothelial growth factor (VEGF) levels were detected at high Ag NP concentrations [65]. These studies however, were obtained with human mesenchymal stem cells

Near-infrared dye loaded polymeric nanoparticles for cancer imaging and therapy and cellular response after laser-induced heating

• Tingjun Lei,
• Alicia Fernandez-Fernandez,
• Romila Manchanda,
• Yen-Chih Huang and
• Anthony J. McGoron

Beilstein J. Nanotechnol. 2014, 5, 313–322, doi:10.3762/bjnano.5.35

• hyperthermia (HT). HT is currently used in clinical trials for cancer therapy in combination with radiotherapy and chemotherapy. One of the potential problems of HT is that it can up-regulate hypoxia-inducible factor-1 (HIF-1) expression and enhance vascular endothelial growth factor (VEGF) secretion. Results

• of both transcription factors. Keywords: hypoxia-inducible factor-1; IR820; nanoparticle; poly(glycerol malate co-dodecanedioate) (PGMD); vascular endothelial growth factor; Introduction The synthesis and development of novel polymers and their use for nanoparticle (NP) synthesis has been an

• endothelial growth factor (VEGF), and poor lymphatic clearance from tumor sites [4]. Because of these advantages, we synthesized a new formulation of polymeric NPs for image-guided therapy based on the polymer poly(glycerol malate co-dodecanedioate) (PGMD) developed in our lab. The work described in this